Table 1 Baseline characteristics of the study cohort
From: On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
All | G4 | G5 | G6 | ||
|---|---|---|---|---|---|
Subtype | HR−/HER2− | 87 (29.3%) | 19 (19%) | 43 (30.9%) | 25 (43.1%) |
HR+/HER2− | 138 (46.5%) | 53 (53%) | 85 (61.2%) | 0 (0%) | |
HER2+ | 72 (24.2%) | 28 (28%) | 11 (7.9%) | 33 (56.9%) | |
Response | no pCR | 235 (79.1%) | 81 (81%) | 125 (89.9%) | 29 (50%) |
pCR | 62 (20.9%) | 19 (19%) | 14 (10.1%) | 29 (50%) | |
On-treatment biopsy | tu+ | 207 (69.7%) | 69 (69%) | 112 (80.6%) | 26 (44.8%) |
tu− | 90 (30.3%) | 31 (31%) | 27 (19.4%) | 32 (55.2%) | |
cT stage | T1 | 25 (8.4%) | 0 (0%) | 11 (7.9%) | 14 (24.1%) |
T2 | 181 (60.9%) | 68 (68%) | 81 (58.3%) | 32 (55.2%) | |
T3 | 42 (14.1%) | 16 (16%) | 17 (12.2%) | 9 (15.5%) | |
T4 | 49 (16.5%) | 16 (16%) | 30 (21.6%) | 3 (5.2%) | |
cN stage | N0 | 125 (42.1%) | 43 (43%) | 51 (36.7%) | 31 (53.4%) |
N1-3 | 171 (57.6%) | 57 (57%) | 88 (63.3%) | 26 (44.8%) | |
NA | 1 (0.3%) | 0 (0%) | 0 (0%) | 1 (1.7%) | |
Grading | G1-2 | 156 (52.5%) | 55 (55%) | 76 (54.7%) | 25 (43.1%) |
G3 | 136 (45.8%) | 40 (40%) | 63 (45.3%) | 33 (56.9%) | |
NA | 5 (1.7%) | 5 (5%) | 0 (0%) | 0 (0%) | |
Histology | NST | 268 (90.2%) | 89 (89%) | 122 (87.8%) | 57 (98.3%) |
Lobular | 23 (7.7%) | 9 (9%) | 14 (10.1%) | 0 (0%) | |
Other | 6 (2%) | 2 (2%) | 3 (2.2%) | 1 (1.7%) | |
TILs Median = 8, IQR = 10 | < 30% ≥ 30% | 267 (89.9%) 30 (10.1%) | 91 (91.0%) 9 (9.0%) | 129 (92.8%) 10 (7.2%) | 47 (81.0%) 11 (19.0%) |
Ki-67 Median = 15.4, IQR = 22.7 | ≥ 15% < 15% NA | 149 (50.2%) 142 (47.8%) 6 (2.0%) | 55 (55.0%) 41 (41.0%) 4 (4.0%) | 72 (51.8%) 65 (46.8%) 2 (1.4%) | 15 (25.9%) 43 (74.1%) 0 (0%) |